The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results.
Michael J. Morris
Consultant or Advisory Role - Bayer (U); Janssen (U); Millennium
Research Funding - Bayer; Sanofi
Martin Edwin Gleave
Employment or Leadership Position - Vancouver Prostate Centre (U)
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; Janssen; Oncogenex
Stock Ownership - Oncogenex
Research Funding - Astellas Pharma; AstraZeneca; Janssen
Andrew J. Armstrong
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Dendreon; Janssen; Medivation/Astellas; Sanofi
Honoraria - Dendreon; Pfizer; Sanofi
Research Funding - Active Biotech Ipsen; Dendreon; Janssen; Medivation; Novartis; Pfizer; Sanofi
Michael Anthony Carducci
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi
Fred Saad
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Kristine Peregrino Lacuna
No relevant relationships to disclose
Howard I. Scher
No relevant relationships to disclose